Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data
Company Posts Solid Q2 Sales Despite REGEN-COV Drop
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.
You may also be interested in...
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.
As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.
The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.